Earnings Summary on United Therapeutics
Key PointsGAAP revenue rose 12% year over year to $798.6 million in Q2 2025 but missed consensus by $3.27 million.GAAP…
267,600€
2,02%
Echtzeit-Aktienkurs United Therapeutics Corp.
Bid:
Ask:
Nachrichten zur United Therapeutics Corp. Aktie
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
IRW-News: Thiogenesis Therapeutics Corp.: Thiogenesis erhält positive Rückmeldung zur Einreichung eines IMPD für die klinische Phase-2a-Studie zu MASH bei Kindern in Europa und Bewilligung für Kernpatent in der EU
IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis erhält positive Rückmeldung zur Einreichung eines IMPD für die klinische Phase-2a-Studie zu MASH bei Kindern…
IRW-News: Thiogenesis Therapeutics Corp.: Thiogenesis gibt zweites Prüfzentrum bekannt, beginnt mit der Rekrutierung für die klinische Phase-2-Studie MELAS und veröffentlicht Update
IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis gibt zweites Prüfzentrum bekannt, beginnt mit der Rekrutierung für die klinische Phase-2-Studie MELAS und veröffentlicht…
United Therapeutics: Tanking On Rivals PAH Data - Id Consider Buying Stock
…
IRW-News: Thiogenesis Therapeutics Corp.: Thiogenesis gibt FDA-Genehmigung für seinen Antrag auf Zulassung eines neuen Prüfpräparats (IND) für eine klinische Phase-2-Studie zum Leigh-Syndrom-Spektrum bekannt
IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis gibt FDA-Genehmigung für seinen Antrag auf Zulassung eines neuen Prüfpräparats (IND) für eine klinische Phase-2-Studie…
Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
IRW-News: Thiogenesis Therapeutics Corp.: Thiogenesis leitet klinische Phase-2-Studie zur mitochondrialen Enzephalomyopathie mit Laktatazidose und schlaganfallähnlichen Episoden (MELAS) ein
IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis leitet klinische Phase-2-Studie zur mitochondrialen Enzephalomyopathie mit Laktatazidose und schlaganfallähnlichen Episoden (MELAS) einSan Diego, Kalifornien,…
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies…
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies…
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.…
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…
United Therapeutics: Dont Fear The Patent Expiration Too Much
…
United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
United Therapeutics president Michael Benkowitz sells $3.57 million in stock By Investing.com
United Therapeutics president Michael Benkowitz sells $3.57 million in stock…
Investing in United Therapeutics (NASDAQ:UTHR) five years ago would have delivered you a 316% gain
We think all investors should try to buy and hold high quality multi-year winners. And weve seen some truly amazing...…
United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy
…
United Therapeutics: One To Believe In Despite Competitive Threats
…
United Therapeutics Q3 Earnings & Sales Beat Estimates
UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.…
Futures: Nvidia Rallies To New Highs
Stocks to watch include Uber Technologies and United Therapeutics.…
Futures Lower As Nvidia, Tesla Fall
Texas Roadhouse, Uber and United Therapeutics are among the best stocks to watch.…
United Therapeutics könnte mit neuen TYVASO-Indikationen und künstlichen Organen seine Umsätze auf 16 Mrd. USD vervielfachen. Flat Base-Breakout!
United Therapeutics (UTHR) ist auf die Entwicklung und Kommerzialisierung von Produkten zur Behandlung der pulmonal-arterielle Hypertonie (PAH) spezialisiert. Vor allem…
Opening Bell: Wall Street startet behauptet; UnitedHealth, Goldman Sachs, Citigroup, United Therapeutics im Fokus
Am Dienstag sieht es zunächst nach einem ruhigen Handelsauftakt an der New Yorker Wall Street aus. Zum Wochenauftakt hatte der…
Opening Bell: Citigroup, Goldman Sachs, United Health, Walgreens, Trump Media, United Therapeutics
Der Rekordlauf an der Wall Street setzte sich auch zu Wochenbeginn fort. Erneut erklommen Dow Jones und S&P 500 neue…
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative…
Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"
United Therapeutics (UTHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.…
Liquidia surges after United Therapeutics request for preliminary injunction denied (update)
…
Earnings call: United Therapeutics reports strong Q1 with record revenue By Investing.com
Earnings call: United Therapeutics reports strong Q1 with record revenue…
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
United Therapeutics (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the companys top line.…
United Therapeutics motion for restraining order over Liquidias Yutrepia denied
…
United Therapeutics CEO sells over $7 million in company stock By Investing.com
United Therapeutics CEO sells over $7 million in company stock…
United Therapeutics initiates $1 billion stock buyback By Investing.com
United Therapeutics initiates $1 billion stock buyback…
United Therapeutics: Neutral Stance On Tyvasos Patent Challenges And Future Growth Prospects
…
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and…